American Kidney Fund Survey Underscores Need to Expand Testing for Chronic Kidney Disease and Increase Awareness of Rare Kidney Diseases
April 07, 2022 09:00 ET
|
American Kidney Fund
ROCKVILLE, Md., April 07, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today released survey findings that provide new insights on the level of awareness among health care providers about...
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
April 05, 2022 20:29 ET
|
Novartis Pharma AG
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized by...
Global Liver Institute Leads Second Annual Rare Liver Diseases Month
February 01, 2022 10:41 ET
|
Global Liver Institute
Washington, DC, USA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI), a patient-led liver health nonprofit operating globally, is proud to announce today the launch of its second...
CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO
October 12, 2021 10:12 ET
|
Curative Biotechnology, Inc.
Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients, Late-Stage Rabies Therapeutic and Age-related Macular Degeneration Boca Raton, FL, Oct. 12, 2021 ...
The Oligonucleotide Therapeutics Society Celebrates Another Remarkable Annual Meeting
October 09, 2021 12:00 ET
|
The Oligonucleotide Therapeutics Society
SAN DIEGO, Oct. 09, 2021 (GLOBE NEWSWIRE) -- The Oligonucleotide Therapeutics Society's 17th Annual Meeting was held virtually the second year in a row and was once again phenomenally successful....
Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech
September 29, 2021 07:00 ET
|
Fortress Biotech, Inc.
Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech1 AstraZeneca intends to advance and...
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF
December 15, 2020 19:17 ET
|
Novartis International AG
The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF)Potential Q1 2021 sNDA approval...
Axiom will be Presenting and Exhibiting at Clinical Trials in Rare Diseases 2020: A Virtual Event
December 02, 2020 11:36 ET
|
Axiom Real-Time Metrics Inc
TORONTO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services, is a presenting sponsor and exhibitor at Clinical Trials...
AskBio and Selecta Biosciences Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia
November 19, 2020 08:00 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. and WATERTOWN, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio) and Selecta Biosciences, Inc. (NASDAQ: SELB) today announced that the...
Selecta Biosciences and AskBio Receive FDA Rare Pediatric Disease Designation for their Gene Therapy for Methylmalonic Acidemia
October 20, 2020 08:00 ET
|
Asklepios BioPharmaceutical, Inc.
WATERTOWN, Mass., and Research Triangle Park, N.C., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced the...